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ABSTRACT
Objective: To measure test accuracy of non-invasive
prenatal testing (NIPT) for Down, Edwards and Patau
syndromes using cell-free fetal DNA and identify
factors affecting accuracy.
Design: Systematic review and meta-analysis of
published studies.
Data sources: PubMed, Ovid Medline, Ovid Embase
and the Cochrane Library published from 1997 to 9
February 2015, followed by weekly autoalerts until 1
April 2015.
Eligibility criteria for selecting studies: English
language journal articles describing case–control
studies with ≥15 trisomy cases or cohort studies with
≥50 pregnant women who had been given NIPT and a
reference standard.
Results: 41, 37 and 30 studies of 2012 publications
retrieved were included in the review for Down, Edwards
and Patau syndromes. Quality appraisal identified high
risk of bias in included studies, funnel plots showed
evidence of publication bias. Pooled sensitivity was
99.3% (95% CI 98.9% to 99.6%) for Down, 97.4%
(95.8% to 98.4%) for Edwards, and 97.4% (86.1% to
99.6%) for Patau syndrome. The pooled specificity was
99.9% (99.9% to 100%) for all three trisomies. In
100 000 pregnancies in the general obstetric population
we would expect 417, 89 and 40 cases of Downs,
Edwards and Patau syndromes to be detected by NIPT,
with 94, 154 and 42 false positive results. Sensitivity
was lower in twin than singleton pregnancies, reduced
by 9% for Down, 28% for Edwards and 22% for Patau
syndrome. Pooled sensitivity was also lower in the first
trimester of pregnancy, in studies in the general
obstetric population, and in cohort studies with
consecutive enrolment.
Conclusions: NIPT using cell-free fetal DNA has very
high sensitivity and specificity for Down syndrome, with
slightly lower sensitivity for Edwards and Patau
syndrome. However, it is not 100% accurate and should
not be used as a final diagnosis for positive cases.
Trial registration number: CRD42014014947.
INTRODUCTION
Non-invasive prenatal testing (NIPT) using
cell-free fetal DNA (cffDNA) is a method for
testing for trisomies in the fetus, using a per-
ipheral sample of the pregnant mother’s
blood. It is currently marketed across 61
countries in Europe, Asia, Africa and North
and South America.1 Rapid adoption in the
USA has seen increases in ﬁrst trimester
screening using NIPT, and concurrent
decreases in the ﬁrst trimester combined test
and invasive testing.2 3 People tend to over-
estimate the usefulness of genetic tests, and
misinterpret their meaning.3 It is possible
that pregnant women will interpret a positive
NIPT test as positive diagnosis, and wish to
abort a pregnancy on this basis. A clear
summary of test accuracy for NIPT is neces-
sary for use by doctors and patients for use
in shared and informed decision-making.
Strengths and limitations of this study
▪ This is a full systematic review with searches
across multiple databases dating back to 1997,
and two authors sifting all titles and abstracts.
▪ Two authors extracted data on prepiloted forms
and appraised quality using an adapted QUADAS
2 form.
▪ The meta-analysis included rigorous methods of
data analysis, including bivariate random-effects
regression models, but required a zero-cell cor-
rection to enable model convergence which may
underestimate rather than overestimate accuracy.
▪ The meta-analysis included a series of subgroup
and sensitivity analyses to test for robustness of
our pooled diagnostic accuracy estimates.
▪ The methods are transparent with full protocol
published in PROSPERO in advance of the
review.
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Although a previous review of NIPT test accuracy
exists,4 it does not include two of the largest studies.5 6
In addition the authors use a univariate approach which
is not appropriate for meta-analysis of tests since it over-
looks the fact that sensitivity and speciﬁcity are usually
negatively correlated across studies due to different
thresholds used to deﬁne positive and negative test
results. It has been shown that ignoring this correlation
would be inappropriate.7 The weighted sums of the
reported speciﬁcity are normally used to assess the value
of a test, the properties of the resulting statistics
depends most importantly on this correlation between
the estimates, and it is exactly that is ignored in separate
univariate analyses.8 9 Most importantly, the previous
review does not provide a summary of ﬁndings which
can be applied to a relevant population and used in clin-
ician–patient shared decision-making.
The UK National Screening Committee commissioned
this new review to provide a summary of the accuracy of
NIPT for detection of Down, Edwards and Patau syn-
dromes in ﬁrst trimester pregnancies, to inform their
decision on introduction of this test into current fetal
abnormality screening in the UK.
METHODS
Identification and selection of studies
Ethical approval was granted from the University of
Warwick Biomedical and Scientiﬁc Research Ethics
Committee reference REGO-2015-1446. Searches were
conducted in PubMed, Ovid Medline, Ovid Embase and
the Cochrane Library. The search strategy used a com-
bination of search terms for the NIPT test and trisomies,
and was limited to the English language, (see online
supplementary ﬁle 1). Date limits were 01.01.1997–
09.02.2015. Updating autoalerts in Medline and Embase
were run until 01.04.2015. Individuals and organisations
were contacted for studies not freely available in the
public domain. ClinicalTrials.gov, WHO International
Clinical Trials Registry Platform (ICTRP) Search Portal
and meeting abstracts were also searched for ongoing or
recently completed trials.
Two reviewers independently screened titles and
abstracts of all records obtained. Discrepancies were
resolved by consensus or discussion with a third reviewer.
Inclusion criteria were English language journal articles
which investigated NIPT using cff DNA derived from
maternal blood (serum, plasma, whole blood) in preg-
nant women in any trimester for the detection of Down
(T21), Edwards (T18) or Patau (T13) syndromes in the
fetus. The reference standard was genetic veriﬁcation
through amniocentesis, Chorionic Villus Sampling
(CVS), cordocentesis, fetal pathological examination
after abortion or postnatal phenotypic assessment. We
included studies with any outcomes reported on test
accuracy, or rates of test failure or indeterminate results.
We excluded studies reporting the quantiﬁcation of fetal
cells or DNA or using elevated levels of the whole fetal
DNA or epigenetic markers. We also excluded case–
control studies with fewer than 15 cases and cohort
studies with fewer than 50 pregnant women as well as
studies with incomplete 2×2 data or studies which
reused samples from other included studies in order to
prevent double counting.
Data were extracted by one reviewer and checked by a
second reviewer. Disagreements were resolved by consen-
sus or discussion with a third reviewer. Full data extrac-
tion forms are available from the authors on request.
Quality assessment
The quality of diagnostic accuracy studies was assessed
using a modiﬁed QUADAS-2.10 Quality assessment was
undertaken by one reviewer and checked by a second
reviewer, with disagreements resolved by a third reviewer.
Three modiﬁcations were made. First, an additional sig-
nalling question was added on whether the study
avoided taking the sample for the index test in the
7 days after an invasive test, as fetal fraction may be ele-
vated at this time boosting the performance of NIPT.
Second, a signalling question was added to determine
whether the threshold value was determined using an
independent set of samples, and whether adjustment of
the predeﬁned threshold was avoided, since the thresh-
old for testing positive is expressed as number of SDs
from the mean score for a set of normal samples, rather
than as an absolute threshold. Finally, the standard
QUADAS-2 signalling question determining whether
there was an appropriate interval between index test and
reference standard was removed, as timing of an invasive
test (apart from in relation to invasive testing) would
not affect accuracy. Timing of the NIPT test is important
as fetal fraction and therefore accuracy of NIPT
increases throughout pregnancy, this was included
under applicability of ﬁndings rather than as a source of
bias. We also assessed the role of the sponsor in addition
to QUADAS-2. This included studies that clearly
declared involvement of a sponsor in the design or
conduct of the study or publication, the majority of
authors were employees or shareholders of companies
offering NIPT or cytogenetic tests and/or other conﬂicts
of interest (ie, patents, stock or stock options). Please
see online supplementary ﬁle 2 for full information on
the deﬁnition for the signalling questions of the
QUADAS-2.
Statistical analysis of test accuracy studies
All eligible studies were included in a meta-analysis of
performance of the NIPT test. We extracted data from
the primary studies to obtain the four cell values of a
diagnostic 2×2 table in order to calculate test accuracy
measures. We pooled the sensitivity and speciﬁcity esti-
mates using bivariate random-effects regression models,
as recommended by the Cochrane Diagnostic Test
Accuracy Working Group,11 in order to take the poten-
tial trade-off between sensitivity and speciﬁcity explicitly
into consideration and incorporate this negative
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correlation into the analysis.7 We added a 0.5 cell correc-
tion to each cell where a zero was encountered. We
stratiﬁed test accuracy measures according to condition
(T21, T18 and T13).
Meta-analysis, subgroup and sensitivity analyses
We used sensitivity, subgroup and meta-regression ana-
lyses to explore potential sources of heterogeneity in test
accuracy estimates across studies. The following variables
were selected a priori as potential sources of heterogen-
eity: study design (cohort with consecutive sampling vs
others), population risk (general, high-risk, others),
population (twins vs others), ﬁrst trimester (100% vs
other), test type (MPSS, DANSR, single nucleotide poly-
morphism (SNP) technology) and publication year
(2007–2013 vs 2014–2015). We conducted a series of
sensitivity analyses to check the robustness of the results.
We excluded all studies with zero cases of true positive
and false negative results. We used Cook’s distance to
identify particularly inﬂuential studies and created a
scatter plot of the standardised predicted random effects
(standardised level 2 residuals) to check for outliers.12
We reﬁtted the model leaving out outliers and very inﬂu-
ential studies.
We constructed 3×2 tables to examine the inﬂuence of
the number of test failures and indeterminate results on
the pooled test accuracy estimates.13 Test failures occur
where the NIPT test has failed to produce any result,
and indeterminate results where the test result is in a
mid-range which is neither positive nor negative. Test
failures can occur for a variety of reasons, and some-
times the cause is unknown. Test failures and indeter-
minate results are not included in the 2×2 tables
reported, and this can lead to overestimates of sensitivity
and speciﬁcity.14 We included all failures of the NIPT
test, regardless of whether repeating the test on the
same or a new blood sample would have given a result,
but we did not include failures which could be rectiﬁed
by good quality assurance procedures (such as insufﬁ-
cient blood or dropped samples). For the 3×2 tables we
considered the following three scenarios, all
non-evaluable results: (1) considered to be positive
results to reﬂect use of the NIPT as triage for invasive
testing,14 (2) considered to be negative results to reﬂect
use of NIPT as an add-on to the combined test14 and (3)
follow intention to diagnose principle to account for the
ﬁrst two approaches overestimating speciﬁcity and sensi-
tivity, respectively.13 Intention to diagnose was deﬁned as
“including non-evaluable results either in the ‘false
negative’ or the ‘false positive’ cell of a 2×2 table (worst
case scenario) according to the results of the reference
standard”. For the intention to diagnose principle, all
non-evaluable positive results were assumed to be false
negative and all non-evaluable negative results were
assumed to be false positive. Where the reference stand-
ard results were not reported for these cases, we
assumed that they had the same prevalence of trisomy as
those in the rest of the same study.
In the subgroup analyses, we computed pooled accur-
acy estimates in various strata to determine if accuracy is
higher or lower in speciﬁc subgroups. Summary sensitiv-
ity and speciﬁcity estimates for each subgroup were gen-
erated, along with their 95% CIs. In the linear
meta-regression model, studies are the units of analysis.
We used the meta-regression model to generate relative
diagnostic ORs.15 16 We used Deeks’ funnel plot asym-
metry test to test for publication bias, with p value<0.10
indicating signiﬁcant publication bias.17 All analyses
were performed using Stata V.13 for Windows including
the user written commands metandi, midas, metareg
and mvmeta.12 18–20
RESULTS
Study selection
A total of 2012 records were identiﬁed after duplicates
were removed. One-hundred and eight records
remained after evaluation of title and abstract, of which
41 studies were included in the meta-analysis. Figure 1
summarises the study selection process (see online sup-
plementary ﬁle 3 for included studies and online supple-
mentary ﬁle 4 for reasons of exclusion for 67 full-text
articles).
Characteristics of included studies
Study design, populations, reference standards
Forty-one publications, dating from 2007 to 2015,
reported NIPT results for between 46 and 112 669 preg-
nant women for the main autosomal trisomies in relation
to fetal karyotype or newborn phenotype and fulﬁlled
our inclusion criteria (see online supplementary ﬁle 5).
The majority of studies were cohort studies (n=29),5 6
21–47 with prospective data collection. There were 11
case–control studies48–58 and one of unclear design.59
Thirty studies were undertaken in singleton pregnancies
only,6 21 22 29–33 35–37 40–51 53–59 four studies included
singleton and twin pregnancies,5 28 34 38 with the remain-
der undertaken in twin only (n=3).23 24 39 In four studies
the reporting was unclear.25 26 28 52 The majority of
studies (n=24) used samples from high-risk pregnant
women (positive standard screening, ultrasound abnor-
malities, advanced maternal age, personal or family
history of aneuploidies) undergoing invasive
testing.24 26 28 30 31 33 36–38 41 44 45 47–56 58 59 Six studies
were performed in the general obstetric popula-
tion.6 21 29 35 40 43 Nine studies included pregnant women
with mixed risk factors.5 22 27 32 34 39 42 46 57 In two the
underlying risk was unclear.23 25 Seven studies included
women in the ﬁrst trimester only,6 23 29 30 43 47 48 while
all other studies (n=34) included pregnant women
with an unstated, later or broader gestational age
window.5 21 22 24–28 31–42 44–46 49–59
Testing strategies
Three main testing strategies were pursued by the major-
ity of studies (see online supplementary ﬁle 6). These
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were genome-wide massively parallel shotgun sequencing
(MPSS, n=24 studies),5 21 22 24–28 33–36 41 44–47 49–52
54 55 58 targeted massively parallel sequencing (DANSR,
n=9 studies),6 23 29 31 37 39 43 48 56 and SNP technology
(n=5).30 32 42 53 57 Two studies, performed in real clin-
ical settings, offered more than one NIPT approach.38 40
Dhallan et al59 used a DNA-SNP allelic ratio approach.
In 3 of the 41 studies,21 32 57 some of the maternal
blood samples for NIPT were obtained after invasive
testing and for 34 studies we concluded that tests were
collected before the invasive testing.5 6 22–24 26–31 33–52
54 55 58 In four studies, it was unclear if maternal blood
sampling for NIPT was performed before or after an
invasive procedure.25 53 56 59
Forty studies reported NIPT performance for
T21,5 6 21–49 51–59 36 for T18,5 6 21–36 38–50 53–57 and 30
studies investigated non-invasive detection of
T13.5 6 21 23 25–28 30 32–36 38–47 49 50 53–55 57 Twenty-nine
studies reported test accuracy for all three main auto-
somal trisomies.5 6 21 23 25–28 30 32–36 38–47 49 53–55 57
Methodological quality of included studies
The methodological quality of the 41 included studies,
assessed by QUADAS-210 is summarised in ﬁgures 2 and 3
and online supplementary ﬁle 7. Risk of bias was high
in most studies with 25 of 41 studies considered high
risk in two or more domains, and 14 studies in one
domain. Two were judged as low or unclear risk of bias
in all ﬁve domains. Figure 2 shows that study ﬂow (con-
cerned with patient follow-up) and the role of the
sponsor were the areas with the greatest risk of bias.
Another issue was incomplete or unclear reporting,
particularly of the patient selection process and the
conduct of the index test, which is reﬂected in 21
(51.2%) and 14 (34.1%) of 41 publications scoring an
unclear risk of bias in these two domains, respectively.
The risk of bias regarding the reference standard was
considered low in almost all studies with only one
study classiﬁed as unclear.23 Finally, risk of bias regard-
ing the role of sponsor was deemed high in 23 studies.
There were signiﬁcant concerns regarding applicability
of the included patient spectrum to cffDNA testing
introduction in the ﬁrst trimester (see ﬁgure 3), as 29
of 41 studies had signiﬁcant parts (>20%) of their
populations tested in the second or third trimester
when fetal fraction and therefore accuracy of NIPT is
higher.
Meta-analysis
There was a high likelihood of publication bias, with the
slope coefﬁcients on Deeks’ funnel plot asymmetry test
signiﬁcant for Down syndrome (p=0.0001), Edwards syn-
drome (p=0.0001), and Patau syndrome (p=0.045) (see
ﬁgure 4).
The pooled sensitivity for Down syndrome from bivari-
ate random-effects regression of 40 studies was 99.3%
(98.9% to 99.6%) and the pooled speciﬁcity was 99.9%
(99.9% to 100%). For Edwards syndrome the pooled
sensitivity over 33 studies was 97.4% (95.8% to 98.4%)
and speciﬁcity was 99.9% (99.9% to 100%). For Patau
Figure 1 Preferred Reporting
Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow
chart of included articles.
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syndrome the pooled sensitivity over 24 studies was
97.4% (86.1% to 99.6%) and speciﬁcity was >99.9%
(99.9% to 100%). Table 1 shows these pooled sensitivities
and speciﬁcities applied to populations of pregnant
women taking the test. In the subgroup analysis (table 2)
sensitivity estimates were lower by 6.1% for Down, 10.6%
for Edwards, and 12.3% for Patau syndromes for cohort
studies with consecutive sampling in comparison to all
other studies which are more likely to be subject to spec-
trum bias. Test accuracy did not appear to systematically
differ between DANSR, MPSS or SNP-based test types or
by publication year. Estimates of test sensitivity were
higher in high-risk populations, in studies including
pregnancies in the second and third trimester, and in
singleton pregnancies. In high-risk populations, deﬁned
in a variety of ways, pooled sensitivity estimates were
1.4%, 6.5% and 17.8% higher than in the general obstet-
ric population for Down, Edwards and Patau syndromes,
respectively. Sensitivity estimates were 1.3%, 1.4% and
11.6% lower in studies recruiting all women in their ﬁrst
trimester of pregnancy in comparison to studies includ-
ing women later in pregnancy. The outcomes of test
accuracy of the included studies are summarised in
online supplementary ﬁle 8. A forest plot of the
sensitivity and speciﬁcity from the individual studies with
95% CIs is given in ﬁgure 5.
Test failures
The rate of analytic failure (failure of the cffDNA
testing) ranged from 0% to 12.7%57 and among 5789
pregnancies with resampling, 803 (13.9%) also failed
the repeat cffDNA testing. There were ﬁve papers in this
review that reported indeterminate results (results in a
range deﬁned as neither positive nor negative) for triso-
mies 21, 18 and 13.21 38 49 55 60 ranging from 0% (0/
2042) to 11.1% (5/45). In the study with no indetermin-
ate results they used eight-plex testing, and where the
initial score was indeterminate they repeated using
one-plex which corrected any indeterminate results.
There is some evidence that the rate of test failure is
higher when gestational age is lower, and in trisomic
pregnancies. Pergament et al32 found that failure rate at
<9 weeks was 26/95 (27.4%), between 9.0 and 9.9 weeks
was 6/50 (12.0%), and more than 10 weeks was 53/900
(5.9%). The same study found aneuploidy incidence was
increased (20/86 (23.3%)) in samples that did not
return a result when compared with the aneuploidy inci-
dence in samples with a cffDNA testing result (105/966
Figure 2 Proportion of studies
with low, high or unclear risk of
bias using QUADAS 2.
Figure 3 Proportion of studies
with low, high and unclear
concerns regarding applicability
using QUADAS 2.
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(10.9%), p=0.004). Norton et al6 did not ﬁnd an associ-
ation between test failure and gestational age in 18 510
women between 10 and 14 weeks gestation, but found
that the prevalence of aneuploidy in the group with test
failure (1 in 38 (2.7%)) was higher than the prevalence
of 1 in 236 (0.4%) in the overall cohort (p<0.001).
Including test failures in an intention to diagnose ana-
lysis in the meta-analysis decreased sensitivity estimates
by 1.7% for Down, 1.6% for Edwards and 7.1% for Patau
syndrome, and decreased speciﬁcity estimates by nearly
2% for all three trisomies. Excluding test failures from
the calculations of test accuracy may have caused over-
estimation of accuracy. Similarly in the subgroup analysis
sensitivity estimates were lower by 6.1% for Down, 10.6%
for Edwards, and 12.3% for Patau syndromes for cohort
studies with consecutive sampling in comparison to all
other studies. Test accuracy did not appear to differ sys-
tematically between DANSR, MPSS or SNP technology,
or by publication year. Estimates of test sensitivity were
higher in high-risk populations, in studies including
pregnancies in the second and third trimester, and in
singleton pregnancies. In high-risk populations, deﬁned
in a variety of ways, pooled sensitivity estimates were
1.4%, 6.5% and 17.8% higher than in the general
obstetric population for Down, Edwards and Patau syn-
dromes, respectively. Sensitivity estimates were 1.3%,
1.4% and 11.6% lower in studies recruiting all women in
their ﬁrst trimester of pregnancy in comparison to
studies including women later in pregnancy. Twin preg-
nancies had 8.3% lower sensitivity estimates than single-
tons for Down syndrome. This difference was 20.6% for
Edwards syndrome, but there was only one study for
Patau syndrome so we were unable to provide a pooled
estimate for twins. Sensitivity and subgroup analyses are
reported in table 2.
DISCUSSION
In a systematic review of 2012 articles, we identiﬁed 41
articles on the test accuracy of NIPT. Quality appraisal
using QUADAS-2 indicated high risk of bias, in particu-
lar due to unclear or unsystematic inclusions and exclu-
sions of participants at study entry level as well as at the
level of analysis. Applicability of ﬁndings was of concern
as there is still very limited data on the screening popula-
tion available. Pooled sensitivity from the meta-analysis
was 99.3% for T21, 97.4% for T18 and 97.4% for T13,
with pooled speciﬁcity 99.9% (99.9% to 100%) for all
three trisomies. We estimated test accuracy in a high-risk
population of 10 000 pregnancies where 3.3% of fetuses
have Down syndrome, 1.5% have Edwards syndrome and
0.5% have Patau syndrome. There would be 324 cases of
Down syndrome detected, with 9 missed and 31 false
positive results, 140 cases of Edwards syndrome detected
with 11 missed and 26 false positive results, and 47 cases
of Edwards syndrome detected, with 3 missed and 7
false positive results (table 1). In the general obstetric
population where prevalence of trisomy is lower, there
would be a lower positive predictive value. In 100 000
pregnancies in the general obstetric population we
would expect 417, 89 and 40 cases of Downs, Edwards
and Patau syndromes to be detected by NIPT, with 94,
154 and 42 false positive results. Therefore it is vital to
follow a positive NIPT test with an invasive diagnostic
test (amniocentesis or CVS) to conﬁrm the presence of
trisomy, if the woman is considering termination of preg-
nancy on the basis of trisomy.
The strengths of this systematic review included a com-
prehensive search of the literature, with quality appraisal
of all included studies, with two authors sifting studies
for inclusion, extracting data and appraising quality. The
meta-analysis included rigorous methods of data analysis,
including bivariate random-effects regression models
and HSROC curve analysis. We also conducted a series
of subgroup analyses and sensitivity analyses to test for
robustness of our pooled diagnostic accuracy estimates.
Homogeneous subgroup and sensitivity analysis
summary accuracy estimates were generally similar to the
overall estimates. We added predeﬁned covariates to the
model using meta-regression analyses to explain hetero-
geneity but considerable statistical heterogeneity
remained. For some of the subgroup analyses, the rela-
tively small number of studies available limited the gen-
eralisability of such pooled accuracy estimates. Finally we
applied zero cell continuity correction of 0.5 to each cell
of a study where a zero is encountered which tends to
underestimate rather than overestimate test accuracy.
The ﬁndings of our review are in line with the results
from previous reviews stating that NIPT has high per-
formance in terms of sensitivity and speciﬁcity,61 62 that
speciﬁcity is slightly higher than sensitivity,61 that the test
performance is greater for T21 than for T18 and T13,4
Figure 4 Deeks’ funnel plot for
Down (left) Edwards (centre) and
Patau (right) syndromes. A
vertical pattern would indicate no
bias, slope is associated with
publication bias.
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Table 1 Summary of findings applied to high risk and general obstetric population
Condition
Summary
accuracy
Median
prevalence Outcomes
Positive
predictive
value
Probability of
false negative Implications
General obstetric population (100 000 pregnancies)
Down syndrome Sensitivity=95.9%
Specificity=99.9%
(6 studies)
0.43% TP=417
FP=94
TN=99471
FN=18
82% 1 in 5570 With prevalence of 0.4%, 435 of 100 000 pregnancies will be affected
by Down syndrome. Of these 417 will be detected and 18 missed by
cffDNA. Of the 99 565 who do not have Down syndrome, 94 will
receive a false positive result. Therefore 82% of pregnancies which
test positive will have Down syndrome
Edwards
syndrome
Sensitivity=86.5%
Specificity=99.8%
(5 studies)
0.10% TP=89
FP=154
TN=99744
FN=14
37% 1 in 7194 With prevalence of 0.1%, 102 of 100 000 pregnancies will be affected
by Edwards syndrome. Of these 89 will be detected and 14 missed
by cffDNA. Of the 99 898 who do not have Edwards syndrome, 154
will receive a false positive result. Therefore 37% of pregnancies
which test positive will have Edwards syndrome
Patau syndrome Sensitivity=77.5%
Specificity=>99.9%
(5 studies)
0.05% TP=40
FP=42
TN=99906
FN=12
49% 1 in 8506 With prevalence of 0.05%, 52 of 100 000 pregnancies will be affected
by Patau syndrome. Of these 40 will be detected and 12 missed by
cffDNA. Of the 99 948 who do not have Patau syndrome, 42 will
receive a false positive result. Therefore 49% of pregnancies which
test positive will have Patau syndrome
High-risk population (10 000 pregnancies)
Down syndrome Sensitivity=97%
Specificity=99.7%
(22 studies)
3.33% TP=324
FP=31
TN=9636
FN=9
91% 1 in 1054 With prevalence of 3.3%, 333 of 10 000 pregnancies will be affected
by Down syndrome. Of these 324 will be detected and 9 missed by
cffDNA. Of the 9667 who do not have Down syndrome, 31 will
receive a false positive result. Therefore 91% of those who test
positive will have Down syndrome
Edwards
syndrome
Sensitivity=93%
Specificity=99.7%
(19 studies)
1.50% TP=140
FP=26
TN=9824
FN=11
84% 1 in 930 With prevalence of 1.5%, 151 of 10 000 pregnancies will be affected
by Edwards syndrome. Of these 140 will be detected and 11 missed
by cffDNA. Of the 9850 who do not have Edwards syndrome, 26 will
receive a false positive result. Therefore 84% of those who test
positive will have Edwards syndrome
Patau syndrome Sensitivity=95%
Specificity=99.9%
(11 studies)
0.50% TP=47
FP=7
TN=9943
FN=3
87% 1 in 4265 With prevalence of 0.5%, 50 of 10 000 pregnancies will be affected
by Patau syndrome. Of these 47 will be detected and 3 missed by
cffDNA. Of the 9950 who do not have Patau syndrome, 7 will receive
a false positive result. Therefore 87% of those who test positive will
have Patau syndrome
Median prevalence determined from cohort studies included in meta-analysis for relevant populations. Estimates of sensitivity and specificity are from meta-analysis sub-groups for studies in
high risk and general obstetric populations. The systematic review investigated test accuracy of non-invasive prenatal testing using cell-free DNA derived from maternal blood (serum, plasma,
whole blood) in pregnant women in any trimester for the detection of Down, Edwards or Patau syndromes in the fetus. The reference standard was genetic verification through amniocentesis,
CVS, cordocentesis, fetal pathological examination after abortion and postnatal phenotypic assessment. Findings should be interpreted with caution. Assessment using QUADAS-2 identified
high risk of bias in included studies, particularly for selection of women and flow. Deeks’ funnel plots indicated there was high risk of publication bias in included studies. Zero-cell corrections
may have reduced accuracy estimates.
cffDNA, cell-free fetal DNA; CVS, Chorionic Villus Sampling; FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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Table 2 Accuracy estimates from sensitivity and subgroup analyses of the included studies by different study characteristics†
Down (trisomy 21) Edwards (trisomy 18) Patau (trisomy 13)
Variables N SN (95% CI) SP (95% CI) n SN (95% CI) SP (95% CI) n SN (95% CI) SP (95% CI)
All studies 40 0.993 (0.989 to 0.996) 0.999 (0.999 to 1.000) 33 0.974 (0.958 to 0.984) 0.999 (0.999 to 1.000) 24 0.974 (0.861 to 0.996) 1.000 (0.999 to 1.000)
Sensitivity analyses
Excluding outliers‡ 37 0.993 (0.989 to 0.996) 1.000 (0.999 to 1.000) 32 0.977 (0.961 to 0.986) 0.999 (0.999 to 1.000) 22 0.977 (0.818 to 0.998) 1.000 (0.999 to 1.000)
Test failures
Assuming all+ve 40 0.997 (0.990 to 0.999) 0.981 (0.972 to 0.988) 33 0.973 (0.956 to 0.983) 0.983 (0.974 to 0.990) 24 0.979 (0.873 to 0.997) 0.981 (0.966 to 0.989)
Assuming all−ve 40 0.962 (0.948 to 0.973) 1.000 (0.999 to 1.000) 33 0.942 (0.913 to 0.962) 0.999 (0.999 to 1.000) 24 0.885 (0.796 to 0.939) 1.000 (0.999 to 1.000)
Intention to diagnosis 40 0.976 (0.959 to 0.986) 0.981 (0.972 to 0.989) 33 0.958 (0.927 to 0.976) 0.983 (0.973 to 0.990) 24 0.903 (0.811 to 0.953) 0.981 (0.966 to 0.989)
Assuming all+ve 40 0.994 (0.989 to 0.997) 0.999 (0.999 to 1.000) 33 0.974 (0.958 to 0.985) 0.999 (0.999 to 1.000) 24 0.974 (0.863 to 0.996) 1.000 (0.999 to 1.000)
Assuming all−ve 40 0.993 (0.987 to 0.996) 0.999 (0.999 to 1.000) 33 0.970 (0.945 to 0.984) 0.999 (0.999 to 1.000) 24 0.976 (0.855 to 0.996) 1.000 (0.999 to 1.000)
Intention to diagnosis 40 0.993 (0.988 to 0.996) 0.999 (0.999 to 1.000) 33 0.972 (0.950 to 0.985) 0.999 (0.999 to 1.000) 24 0.976 (0.855 to 0.996) 1.000 (0.999 to 1.000)
Subgroup analyses
Study design
Cohort 5 0.932 (0.853 to 0.971) 0.999 (0.996 to 1.000) 4 0.868 (0.591 to 0.968) 0.998 (0.994 to 0.999) 3 0.851 (0.498 to 0.971) 0.999 (0.995 to 1.000)
Others 35 0.976 (0.963 to 0.985) 0.998 (0.997 to 0.999) 29 0.941 (0.914 to 0.960) 0.998 (0.997 to 0.999) 21 0.970 (0.852 to 0.994) 1.000 (0.999 to 1.000)
Population risk
General 6 0.959 (0.874 to 0.987) 0.999 (0.998 to 1.000) 4 0.865 (0.627 to 0.961) 0.998 (0.997 to 0.999) 4 0.775 (0.135 to 0.987)§ 1.000 (0.999 to 1.000)
High 22 0.973 (0.951 to 0.985) 0.997 (0.994 to 0.998) 19 0.930 (0.892 to 0.955) 0.997 (0.995 to 0.999) 11 0.953 (0.864 to 0.985) 0.999 (0.996 to 1.000)
Others 12 0.974 (0.940 to 0.989) 0.999 (0.998 to 0.999) 10 0.958 (0.907 to 0.982) 0.999 (0.999 to 1.000) 9 0.988 (0.547 to 1.000) 1.000 (0.999 to 1.000)
Population
Others 36 0.977 (0.965 to 0.985) 0.998 (0.997 to 0.999) 31 0.943 (0.917 to 0.960) 0.998 (0.997 to 0.999) 23 0.974 (0.861 to 0.996) 1.000 (0.999 to 1.000)
Twins 4 0.894 (0.750 to 0.960) 0.996 (0.996 to 0.996) 2 0.737 (0.202 to 0.969)§ 0.998 (0.986 to 1.000) 1*
First trimester
100% 7 0.960 (0.887 to 0.987) 0.999 (0.998 to 1.000) 5 0.925 (0.814 to 0.972) 0.998 (0.997 to 0.999) 5 0.850 (0.770 to 0.906)§ 0.999 (0.998 to 0.999)
Others 33 0.973 (0.958 to 0.983) 0.998 (0.997 to 0.999) 28 0.939 (0.910 to 0.960) 0.998 (0.997 to 0.999) 19 0.966 (0.872 to 0.992) 1.000 (0.999 to 1.000)
Test types
DANSR 9 0.958 (0.898 to 0.983) 0.999 (0.997 to 1.000) 6 0.948 (0.879 to 0.979) 0.998 (0.996 to 0.999) 3 0.606 (0.216 to 0.895) 1.000 (0.998 to 1.000)
MPSS 25 0.978 (0.963 to 0.987) 0.998 (0.997 to 0.999) 23 0.936 (0.899 to 0.960) 0.998 (0.997 to 0.999) 16 0.959 (0.989 to 0.991) 1.000 (0.999 to 1.000)
SNP technology 4 0.984 (0.937 to 0.996) 0.998 (0.993 to 1.000) 4 0.918 (0.751 to 0.976) 0.998 (0.994 to 1.000) 5 0.870 (0.647 to 0.960) 0.998 (0.992 to 0.999)
Publication year
2007–2013 18 0.977 (0.958 to 0.988) 0.998 (0.995 to 0.999) 15 0.954 (0.919 to 0.975) 0.998 (0.995 to 0.999) 9 0.933 (0.799 to 0.980) 0.999 (0.993 to 1.000)
2014–2015 22 0.966 (0.939 to 0.981) 0.999 (0.998 to 0.999) 18 0.915 (0.853 to 0.952) 0.996 (0.998 to 0.999) 15 0.984 (0.770 to 0.999) 1.000 (0.999 to 1.000)
*Bivariate model inestimable for only one study in the subgroup.23
†Excluded studies with inestimable sensitivity (T21—Hall 2014; T18—Comas 2014, Hall 2014, Zhang (twins) 2015; T13—Sehnert 2011, Beamon 2014, Comas 2014, Bevilacqua 2015, Wax
2015, Zhang (twins) 2015).
‡Excluded outliers (T21—Dhallan 2007, Chiu 2011, Sparks 2012; T18—Chen 2011; T13—Chen 2011, Palomaki 2012).
‡p Value for subgroup differences <0.05 (statistically significant).
SN, sensitivity; SNP, single nucleotide polymorphism; SP, specificity.
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Figure 5 Individual and pooled
sensitivity and specificity for
non-invasive prenatal testing
(NIPT) for the detection of
a. Down syndrome b. Edwards
syndrome and c. Patau
syndrome.
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and that NIPT is less successful in twin pregnancies than
in singleton pregnancies.4 However, we found evidence
of signiﬁcant publication bias, converted results into a
format interpretable by clinicians, and concluded that
the test is not diagnostic. There are two key differences
between our review and the previous publications. First,
we included more studies, several of which have been
published since the most recent review4 (including two
of the largest studies with test accuracy for 128 510
women).5 6 Second, the two previous reviews conducted
separate pooling of the diagnostic test accuracy measures
using a univariate approach using standard methods for
proportion4 62 which is not recommended for reviews of
test accuracy. Berkey et al63 show that a bivariate
meta-regression is more efﬁcient than separate univari-
ate meta-regressions for assessing study-level covariates,
due to the inclusion of correlation. We used Deeks’
funnel plots and found evidence of publication bias,
whereas the previous review used an Egger’s bias applied
to sensitivity and speciﬁcity separately and found no evi-
dence of bias, although their method may not be appro-
priate for studies of test accuracy.17 Studies with a larger
effective sample size tended to report higher diagnostic
ORs. This may be due to publication bias in large
laboratory cohort or case–control studies with a lack of
systematic or consecutive sampling, or the fact that
studies in the general obstetric population tend to have
lower test accuracy and fewer cases. It may be partly due
to our methods in that the zero-cell correction may dis-
advantage small studies, or simply that the test is per-
formed to a higher standard in larger studies, perhaps
due to more advanced protocols used in later large scale
studies.
The implications for policymakers and clinicians are
that NIPT using cffDNA has very high sensitivity and spe-
ciﬁcity, and can contribute to screening programmes for
Down, Edwards and Patau syndromes. It is clear that test
accuracy is very good but not perfect. This is particularly
true when considering populations in terms of risk and
gestational age. Our subgroup analyses showed that test
performance is better in high-risk populations as well as
in studies including pregnancies in the second and third
trimester. Consideration of NIPT as a screening test for
the general obstetric population primarily tested in the
ﬁrst trimester of pregnancy has to take into account the
lower sensitivity of NIPT in this population. There is also
some indication that higher maternal weight, and con-
ception by in vitro fertilisation (IVF) are potential pre-
dictors of NIPT test failure39 suggesting that NIPT may
not work equally well in all subpopulations. We consider
that for this reason cffDNA should not be regarded as a
diagnostic test and that conﬁrmation of a positive NIPT
result by amniocentesis or CVS is necessary to make a
diagnosis of trisomy. This is essential if parents are consid-
ering termination of pregnancy on the basis of trisomy,
because in the general obstetric population as many as
20% of positive NIPT results for Down syndrome may be
false positive. This proportion will be higher for Edwards
and Patau syndromes. Because the source of cffDNA is
the placenta, conﬁned placental mosaicism may explain a
proportion of discordant NIPT results.64 Furthermore,
early fetal demise of an affected fetus53 64 and unknown
chromosomal abnormality in the mother5 64 can lead to
false positive results. Finally, in some cases discordance
between NIPT and fetal karyotype results might be due to
lab error.64 The role of low fetal fraction as contributor to
false positive or false negative results is unclear: Zhang
et al5 reported no major inﬂuence, whereas Quezada
et al43 found lower fetal fractions in discordant than in
those with concordant results.
Communicating to clinicians and patients that this
genetic test is not perfect will be key for safe implemen-
tation, and pretest and post-test information provision
and counselling for positive and negative NIPT results
should be given careful consideration. The NIPT test
may be particularly attractive to parents who are not con-
sidering termination of pregnancy, but who would like
to know in advance if their pregnancy is affected by a
trisomy, since NIPT gives broadly accurate results,
without the slightly increased risk of miscarriage asso-
ciated with invasive procedures such as amniocentesis
and CVS. The ﬁnal consideration for implementation is
the range of test failure rates from <1% to >12%, with
some evidence that presence of trisomy may be a pre-
dictor of test failure. Quality assurance to minimise test
failures would minimise delays due to repeated testing,
which may be a priority for pregnant women. However,
if the test failure is due to insufﬁcient fetal fraction a
retest is also likely to fail.
This test is used worldwide, mostly provided directly by
private providers rather than national health systems.
Further research into how the test is being interpreted
and understood by clinicians and pregnant women will
be key to understanding the balance of beneﬁts and
harms from the provision of the test. In particular, how
this understanding leads to decisions about whether to
continue the pregnancy, and whether this may be inﬂu-
enced by how the test is presented to parents both by
companies, and by clinicians. Finally if it is implemented
into national screening programmes, keeping accurate
records of outcomes and test failures would enable the
test performance to be evaluated in practice. This may
differ from the test accuracy in the included studies in
this paper, due to the high risk of bias in included
studies of cffDNA, and the unexplained heterogeneity
illustrating the uncertainties in transferring results from
research studies into everyday practice.
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